These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis. Mohamed TK; Batran RZ; Elseginy SA; Ali MM; Mahmoud AE Bioorg Chem; 2019 Apr; 85():253-273. PubMed ID: 30641320 [TBL] [Abstract][Full Text] [Related]
3. Identification of 3, 4-disubstituted pyridine derivatives as novel CDK8 inhibitors. Zhang H; Jing L; Liu M; Goto M; Lai F; Liu X; Sheng L; Yang Y; Yang Y; Li Y; Chen X; Lee KH; Xiao Z Eur J Med Chem; 2021 Nov; 223():113634. PubMed ID: 34147745 [TBL] [Abstract][Full Text] [Related]
4. EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives. Mourad AAE; Farouk NA; El-Sayed EH; Mahdy ARE Life Sci; 2021 Jul; 277():119531. PubMed ID: 33887348 [TBL] [Abstract][Full Text] [Related]
5. Design, molecular docking, in vitro, and in vivo studies of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors with potential activity against hepatocellular carcinoma. Eissa IH; Ibrahim MK; Metwaly AM; Belal A; Mehany ABM; Abdelhady AA; Elhendawy MA; Radwan MM; ElSohly MA; Mahdy HA Bioorg Chem; 2021 Feb; 107():104532. PubMed ID: 33334586 [TBL] [Abstract][Full Text] [Related]
6. New bis([1,2,4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, in silico studies, and anticancer evaluation. Alanazi MM; Mahdy HA; Alsaif NA; Obaidullah AJ; Alkahtani HM; Al-Mehizia AA; Alsubaie SM; Dahab MA; Eissa IH Bioorg Chem; 2021 Jul; 112():104949. PubMed ID: 34023640 [TBL] [Abstract][Full Text] [Related]
7. Discovery of novel pyrazolo[3,4-b]pyridine scaffold-based derivatives as potential PIM-1 kinase inhibitors in breast cancer MCF-7 cells. Nafie MS; Amer AM; Mohamed AK; Tantawy ES Bioorg Med Chem; 2020 Dec; 28(24):115828. PubMed ID: 33166925 [TBL] [Abstract][Full Text] [Related]
8. VEGFR-2 inhibiting effect and molecular modeling of newly synthesized coumarin derivatives as anti-breast cancer agents. Ahmed EY; Abdel Latif NA; El-Mansy MF; Elserwy WS; Abdelhafez OM Bioorg Med Chem; 2020 Mar; 28(5):115328. PubMed ID: 31992477 [TBL] [Abstract][Full Text] [Related]
9. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme. El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967 [TBL] [Abstract][Full Text] [Related]
10. Discovery of new 3-methylquinoxalines as potential anti-cancer agents and apoptosis inducers targeting VEGFR-2: design, synthesis, and Alanazi MM; Alaa E; Alsaif NA; Obaidullah AJ; Alkahtani HM; Al-Mehizia AA; Alsubaie SM; Taghour MS; Eissa IH J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1732-1750. PubMed ID: 34325596 [TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of thienopyrimidine urea derivatives with potential cytotoxic and pro-apoptotic activity against breast cancer cell line MCF-7. Abdelhaleem EF; Abdelhameid MK; Kassab AE; Kandeel MM Eur J Med Chem; 2018 Jan; 143():1807-1825. PubMed ID: 29133058 [TBL] [Abstract][Full Text] [Related]
12. Dual VEGFR-2/PIM-1 kinase inhibition towards surmounting the resistance to antiangiogenic agents via hybrid pyridine and thienopyridine-based scaffolds: Design, synthesis and biological evaluation. Rizk OH; Teleb M; Abu-Serie MM; Shaaban OG Bioorg Chem; 2019 Nov; 92():103189. PubMed ID: 31473473 [TBL] [Abstract][Full Text] [Related]
13. New quinoxaline derivatives as VEGFR-2 inhibitors with anticancer and apoptotic activity: Design, molecular modeling, and synthesis. Alsaif NA; Dahab MA; Alanazi MM; Obaidullah AJ; Al-Mehizia AA; Alanazi MM; Aldawas S; Mahdy HA; Elkady H Bioorg Chem; 2021 May; 110():104807. PubMed ID: 33721808 [TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors. Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536 [TBL] [Abstract][Full Text] [Related]
15. Novel piperazine-chalcone hybrids and related pyrazoline analogues targeting VEGFR-2 kinase; design, synthesis, molecular docking studies, and anticancer evaluation. Ahmed MF; Santali EY; El-Haggar R J Enzyme Inhib Med Chem; 2021 Dec; 36(1):307-318. PubMed ID: 33349069 [TBL] [Abstract][Full Text] [Related]
16. Identification of new [1,2,4]triazolo[4,3-a]quinoxalines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, anticancer evaluation, and in silico studies. Alsaif NA; Taghour MS; Alanazi MM; Obaidullah AJ; Alanazi WA; Alasmari A; Albassam H; Dahab MA; Mahdy HA Bioorg Med Chem; 2021 Sep; 46():116384. PubMed ID: 34479065 [TBL] [Abstract][Full Text] [Related]
17. New benzoxazole derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: design, synthesis, anti-proliferative evaluation, flowcytometric analysis, and Elkady H; Elwan A; El-Mahdy HA; Doghish AS; Ismail A; Taghour MS; Elkaeed EB; Eissa IH; Dahab MA; Mahdy HA; Khalifa MM J Enzyme Inhib Med Chem; 2022 Dec; 37(1):397-410. PubMed ID: 34961427 [TBL] [Abstract][Full Text] [Related]
18. Biological Activity, Apoptotic Induction and Cell Cycle Arrest of New Hydrazonoyl Halides Derivatives. Mohamed MF; Hassaneen HM; Elzayat EM; El-Hallouty SM; El-Manawaty M; Saleh FM; Mohamed Y; El-Zohiry D; Fahmy G; Abdelaal N; Hassanin N; Hossam N Anticancer Agents Med Chem; 2019; 19(9):1141-1149. PubMed ID: 30843494 [TBL] [Abstract][Full Text] [Related]
19. New series of isoxazole derivatives targeting EGFR-TK: Synthesis, molecular modeling and antitumor evaluation. Warda ET; Shehata IA; El-Ashmawy MB; El-Gohary NS Bioorg Med Chem; 2020 Nov; 28(21):115674. PubMed ID: 33065442 [TBL] [Abstract][Full Text] [Related]
20. Discovery of new VEGFR-2 inhibitors based on bis([1, 2, 4]triazolo)[4,3- Alsaif NA; Taghour MS; Alanazi MM; Obaidullah AJ; Al-Mehizia AA; Alanazi MM; Aldawas S; Elwan A; Elkady H J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1093-1114. PubMed ID: 34056992 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]